AMG 102 and Avastin for Recurrent Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2014

Study Completion Date

September 30, 2015

Conditions
Glioblastoma MultiformeGliosarcoma
Interventions
DRUG

AMG 102

AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.

DRUG

Avastin

Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center, Durham

Sponsors

Collaborators (1)

All Listed Sponsors
lead

Katy Peters

OTHER

collaborator

Amgen

INDUSTRY